ArticleCancer medicine2026
Efficacy and Safety of Neoadjuvant Chemotherapy Followed by CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With HR-Positive, HER2-Negative Breast Cancer: A Retrospective Single-Centre Cohort Analysis.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundEndocrine therapy with CDK4/6 inhibitor has been the main treatment for HR+/HER2- breast cancer in the adjuvant setting; however, the data on the application in the neoadjuvant setting is limited. We compared neoadjuvant efficacy and safety of sequential chemotherapy-CDK4/6 inhibitors with chemotherapy alone in HR+/HER2- breast cancer patients.
methodsFemale patients with HR+/HER2- breast cancer who received neoadjuvant therapy at the Fifth Medical Center of the PLA General Hospital from November 2019 to March 2025 were enrolled. The objective response rate (ORR), pathological complete response (pCR), and event-free survival (EFS) between the two treatment groups were analyzed.
resultsAmong the 181 enrolled patients, 142 received chemotherapy alone (NCT cohort) and 39 received CDK4/6 inhibitors plus endocrine therapy (NCT-ET cohort) after chemotherapy as preoperative therapy. Overall pCR was similar across cohorts (3.5% in NCT cohort vs. 2.6% in NCT-ET cohort, p = 1.000), as was ORR (72.5% vs. 69.2%, p = 0.685). The 3-year EFS rate was numerically higher in the NCT-ET cohort (96.7% vs. 83.6%, p = 0.111). However, among patients who failed to achieve partial response (PR) within 4 cycles of chemotherapy, switching to endocrine therapy was associated with improved ORR (61.3% vs. 30.4%, p = 0.005). Overall pCR (3.2% vs. 0.0%, p = 0.356) and 3-year EFS rate (95.7% vs. 78.0%, p = 0.105) were numerically higher in the NCT-ET cohort. The total incidence of grade ≥ 3 adverse effects was higher in the NCT-ET cohort (69.2% vs. 47.8%). However, for patient received endocrine therapy after chemotherapy, grade ≥ 3 events decreased from 66.7% during chemotherapy phase to 20.5% after switching to endocrine therapy.
conclusionsDespite no statistically significant differences in observed overall pCR and 3y-EFS between patients treated with NCT or NCT-ET, the sequential endocrine strategy was associated with improved ORR among patients who did not achieve PR after four cycles of chemotherapy and a lower incidence of adverse events during endocrine therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.